Imagion Biosystems, Ltd. (ASX: IBX) announced that it has secured firm commitments for AU$3.75M (US$2.59M) in new capital following the FDA’s clearance of the company’s IND application for a Phase 2 clinical trial. The raise will fund the commencement of the clinical trial of the MagSense® imaging agent in HER2+ breast cancer. The company has already begun trial activation activities and expects to begin patient recruitment later this year. “We are very pleased with the strong demand we saw fro

June 25, 2026 -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced the closing of its previously announced equity financing with Samsung affiliates including Samsung C&T Corporation. Pursuant to the definitive agreement, the Samsung entities invested $110 million in GRAIL through the purchase of shares of GRAIL common stock at a price of $70.05 per share, representing a long-term investment in support of GRAIL's growth

Novartis will pay biotechnology startup Antares Therapeutics $105 million as part of a multi-target research collaboration to find the Swiss pharmaceutical giant new cancer medicines. According to the terms of the dealannounced Wednesday, Antares stands to gain as much as $1.8 billion in additional payments if it discovers worthwhile targets and hits certain development and commercialization milestones. It’s also eligible for tiered royalties in “the low double-digit range” on resulting products

June 24, 2026 EQT Life Sciences joins new investors Frazier Life Sciences, Forbion, Monograph and Wellington Management, alongside existing investors LifeArc, Oxford Science Enterprises and Oxford University Innovation, in RQ Bio's oversubscribed USD 115 million Series A financing RQ Bio is developing antibody therapies to prevent seasonal influenza in high-risk and immunocompromised populations, with the Series A supporting its clinical progression and broader infectious disease pipeline As

Proceeds expected to support a focused pulmonary hypertension strategy, including a Phase 1b proof-of-concept study evaluating Auxora™ in PAH, with data anticipated mid-2027, and advancement of oral CRAC channel inhibitor CM5480 to IND clearance expected mid-2027 Anticipated cash runway into 2H 2027 with upfront proceeds June 24, 2026 -- CalciMedica, Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company developing novel calcium release-activated calciu

June 22, 2026 -- NanoGhost Ltd., a biotechnology company developing a proprietary targeted drug delivery platform for cancer and other severe diseases, announced today that it has been awarded a new grant from the Israel Innovation Authority to support an innovative collaborative research program with Ben-Gurion University of the Negev via its technology transfer company, BGN. This marks the sixth grant awarded to NanoGhost by the Israel Innovation Authority, reflecting continued confidence in

New funding will power foundational primary cell data generation to advance AI-driven discovery through the company's full product launch. June 22, 2026 -- DropGenie, a biotechnology company advancing next-generation gene editing workflows, today announced the closing of its Seed+ financing to support the launch of its first product. The round was led by Skeleton Key, with new investors Merck Global Health Innovation Fund and CQDM, and existing investors Real Ventures and Anges Québec continuin

Lead program, MMT-205, licensed from MabTics Co., Ltd / Curacle Co., Ltd. is a potential best-in-class bispecific antibody which activates Tie2 and inhibits VEGF, in development for neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME) In connection with the transaction, Memento Medicines has closed a $93M Series A financing, co-led by Forbion, RA Capital Management and Avego BioScience Capital, to support the progress of MMT-205 through IND-enabling and clinical

Memento’s lead asset is a bispecific antibody that blocks VEGF and activates Tie2. The biotech plans to test the candidate in retinal conditions such as neovascular age-related macular degeneration and diabetic macular edema. Memento Medicines has bagged $93 million in series A proceeds, which the Boston biotech plans to funnel toward a newly licensed asset for retinal disorders. In conjunction with the funding round, Memento struck up an exclusive deal with MabTics and Curacle, paying unspecif

Nura Bio, a neuroscience-focused biotech with a novel approach to treat disorders like amyotrophic lateral sclerosis (ALS), pulled in $73.8 million in a series B funding round to support two clinical programs that could potentially address neurological conditions with high unmet need. ALS, in particular, has been a daunting challenge for drugmakers. Only a select few, including Biogen’s Qalsody, have broken through to the market, leaving patients with limited options to treat a devastating and